mounjaro versus semaglutide Ozempic vs Ozempic vs Mounjaro: Comparing GLP‑1
Description
Today we are talking about mitigating 2 other common side effects, constipation and diarrhea
Triple-agonist peptide
Key highlights: Once-daily oral administration Up to 11.8% weight loss over 36 weeks Focus on broader cardiometabolic health outcomes Advancement into Phase III development As obesity remains one of the most significant global health challenges, innovation in oral GLP-1 therapies could help improve accessibility and patient adherence while expanding treatment options beyond injectable therapies
Read the article for insights.
Expert UK guidance on what to expect.
Zepbound
